{
    "clinical_study": {
        "@rank": "156601", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to add a new protease\n      inhibitor (PI), 141W94, to an anti-HIV regimen that includes 2 nucleoside reverse\n      transcriptase inhibitors (NRTIs)."
        }, 
        "brief_title": "Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this double-blind, placebo-controlled, pediatric study, 210 patients are randomized to\n      receive 2 NRTIs plus either 141W94 or placebo. Enrollment of patients is sequential:\n      patients 13 to 18 years of age are enrolled first, followed by children < 13 when the\n      appropriate pediatric dose has been determined. Patients who are unable to swallow capsules\n      will be accrued when a liquid formulation becomes available."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Your child may be eligible for this study if he/she:\n\n          -  Is 6 months - 18 years of age.\n\n          -  Is HIV-positive.\n\n          -  Has a viral load (level of HIV in the body) greater than 10,000 copies/ml.\n\n          -  Is able to take medications by mouth.\n\n          -  Has consent of parent or legal guardian if under 18.\n\n          -  Has a negative pregnancy test within 7 days of study entry.\n\n          -  Agrees to practice abstinence or use effective methods of birth control for 1 month\n             before and throughout the study.\n\n        Exclusion Criteria\n\n        Your child will not be eligible for this study if he/she:\n\n          -  Has a serious illness, including any life-threatening infection or other chronic\n             serious medical condition.\n\n          -  Has an opportunistic (AIDS-related) infection or a serious bacterial infection.\n\n          -  Is allergic to NRTIs.\n\n          -  Is breast-feeding.\n\n          -  Is unlikely to complete the study.\n\n          -  Has received certain medications.\n\n          -  Has received radiation therapy within the past 4 months, or will need to receive it\n             during the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": "210", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002193", 
            "org_study_id": "264C", 
            "secondary_id": "PROA3004"
        }, 
        "intervention": {
            "intervention_name": "Amprenavir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Protease Inhibitors", 
                "Amprenavir", 
                "HIV Protease Inhibitors", 
                "Reverse Transcriptase Inhibitors"
            ]
        }, 
        "keyword": [
            "HIV-1", 
            "Drug Therapy, Combination", 
            "HIV Protease Inhibitors", 
            "RNA, Viral", 
            "VX 478", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "Viral Load"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fort Lauderdale", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33301"
                    }, 
                    "name": "Children's Diagnostic Treatment Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38105"
                    }, 
                    "name": "Saint Jude Children's Hosp / Dept of Infect Diseases"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Safety and Efficacy of 141W94 Plus Current Nucleoside Therapy Versus Current Nucleoside Therapy Alone in Protease-Naive, HIV-Infected Children", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002193"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1999"
    }, 
    "geocoordinates": {
        "Children's Diagnostic Treatment Ctr": "26.122 -80.143", 
        "Saint Jude Children's Hosp / Dept of Infect Diseases": "35.15 -90.049"
    }
}